Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Denton

Showing results (431-440 of 484) with videos related to

Pageof 49
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|May 22, 2018
Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group StudyVeronika K Jaeger, Gabriele Valentini, Eric Hachulla, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 20, 2018
A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's PhenomenonJack D Wilkinson, Sarah A Leggett, Elizabeth J Marjanovic, et al.
Journal of Scleroderma and Related Disorders|May 19, 2025
Recommendations for the local management of digital ulcers in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) 'Ad hoc committee'Corrado Campochiaro, Yossra A Suliman, Dilia Giuggioli, et al.
Lancet (London, England)|May 10, 2016
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trialDinesh Khanna, Christopher P Denton, Angelika Jahreis, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
RMD Open|August 13, 2025
Assessing the <i>MUC5B</i> promoter variant in a large cohort of systemic sclerosis-associated interstitial lung diseaseCarlos Rosa-Baez, Carlos Rangel-Pelaez, Inmaculada Rodriguez-Martin, et al.
Nature Reviews. Rheumatology|March 3, 2025
Publisher Correction: An international perspective on the future of systemic sclerosis researchDavid J Abraham, Carol M Black, Christopher P Denton, et al.
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Annals of the Rheumatic Diseases|January 28, 2025
EULAR recommendations for the treatment of systemic sclerosis: 2023 updateFrancesco Del Galdo, Alain Lescoat, Philip G Conaghan, et al.
NPJ Genomic Medicine|October 5, 2022
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosisMartin Kerick, Marialbert Acosta-Herrera, Carmen Pilar Simeón-Aznar, et al.
Pageof 49

Showing results (431-440 of 484) with videos related to

Sort By:
Pageof 49
Arthritis & Rheumatology (Hoboken, N.J.)|May 22, 2018
Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group StudyVeronika K Jaeger, Gabriele Valentini, Eric Hachulla, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 20, 2018
A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's PhenomenonJack D Wilkinson, Sarah A Leggett, Elizabeth J Marjanovic, et al.
Journal of Scleroderma and Related Disorders|May 19, 2025
Recommendations for the local management of digital ulcers in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) 'Ad hoc committee'Corrado Campochiaro, Yossra A Suliman, Dilia Giuggioli, et al.
Lancet (London, England)|May 10, 2016
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trialDinesh Khanna, Christopher P Denton, Angelika Jahreis, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
RMD Open|August 13, 2025
Assessing the <i>MUC5B</i> promoter variant in a large cohort of systemic sclerosis-associated interstitial lung diseaseCarlos Rosa-Baez, Carlos Rangel-Pelaez, Inmaculada Rodriguez-Martin, et al.
Nature Reviews. Rheumatology|March 3, 2025
Publisher Correction: An international perspective on the future of systemic sclerosis researchDavid J Abraham, Carol M Black, Christopher P Denton, et al.
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Annals of the Rheumatic Diseases|January 28, 2025
EULAR recommendations for the treatment of systemic sclerosis: 2023 updateFrancesco Del Galdo, Alain Lescoat, Philip G Conaghan, et al.
NPJ Genomic Medicine|October 5, 2022
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosisMartin Kerick, Marialbert Acosta-Herrera, Carmen Pilar Simeón-Aznar, et al.
Pageof 49